The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3105429 29 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objectives: To assess whether patients with antiphospholipid syndrome (APS) and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous) compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS. © 2019 Elsevier Inc.
Έτος δημοσίευσης:
2019
Συγγραφείς:
Radin, M.
Sciascia, S.
Erkan, D.
Pengo, V.
Tektonidou, M.G.
Ugarte, A.
Meroni, P.
Ji, L.
Belmont, H.M.
Cohen, H.
Ramires de Jesús, G.
Branch, D.W.
Fortin, P.R.
Andreoli, L.
Petri, M.
Rodriguez, E.
Rodriguez-Pinto, I.
Knight, J.S.
Atsumi, T.
Willis, R.
Gonzalez, E.
Lopez-Pedrera, R.
Rossi Gandara, A.P.
Borges Gualhardo Vendramini, M.
Banzato, A.
Sevim, E.
Barbhaiya, M.
Efthymiou, M.
Mackie, I.
Bertolaccini, M.L.
Andrade, D.
Περιοδικό:
Seminars in Arthritis and Rheumatism
Εκδότης:
W.B. Saunders
Τόμος:
49
Αριθμός / τεύχος:
3
Σελίδες:
464-468
Λέξεις-κλειδιά:
beta2 glycoprotein 1 antibody; phospholipid antibody; biological marker; phospholipid antibody, adjusted global antiphospholipid syndrome score; adult; antiphospholipid syndrome; Article; cardiovascular risk; clinical assessment; comparative study; controlled study; cross-sectional study; female; human; hyperlipidemia; hypertension; major clinical study; male; medical history; middle aged; priority journal; recurrence risk; recurrent disease; thrombosis; antiphospholipid syndrome; blood; clinical trial; complication; follow up; global health; immunology; multicenter study; procedures; prognosis; register; retrospective study; risk assessment; risk factor; severity of illness index; thrombosis, Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Biomarkers; Cross-Sectional Studies; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Prognosis; Recurrence; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Thrombosis
Επίσημο URL (Εκδότης):
DOI:
10.1016/j.semarthrit.2019.04.009
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.